These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 18555482)

  • 1. Treatment of refractory prostate cancer with somatostatin analogues and glucocorticoids.
    Trafalis DT; Athanassiou AE
    J BUON; 2008; 13(2):295-6. PubMed ID: 18555482
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Stadler WM; Michaelis LC; Ratain MJ
    J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of systemic cytotoxic therapy for prostate cancer.
    Chang SS; Kibel AS
    BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin and growth hormone regulation in cancer.
    Manni A
    Biotherapy; 1992; 4(1):31-6. PubMed ID: 1347453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?
    Berry WR
    Nat Clin Pract Oncol; 2005 Apr; 2(4):180-1. PubMed ID: 16264926
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions.
    Liu Y
    Cancer Lett; 2006 Jul; 239(1):21-6. PubMed ID: 16126334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long and winding road: the role of chemotherapy for hormone-refractory prostate cancer.
    Higgins GS; Stewart GD; McNeill SA; McLaren DB
    Int J Clin Pract; 2007 Dec; 61(12):1964-5. PubMed ID: 17997800
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum.
    Mahajna J; Dotan N; Zaidman BZ; Petrova RD; Wasser SP
    Nutr Cancer; 2009; 61(1):16-26. PubMed ID: 19116872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.
    McLeod DG
    Eur Urol; 2008 May; 53(5):898-9. PubMed ID: 18201816
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues.
    Bamias A; Dimopoulos MA
    Eur Urol; 2008 May; 53(5):899-900. PubMed ID: 18201817
    [No Abstract]   [Full Text] [Related]  

  • 11. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: moving forward by reinventing the wheel...but this time it is round.
    Raghavan D; Klein EA
    J Clin Oncol; 2008 Oct; 26(28):4535-6. PubMed ID: 18626003
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain metastases in hormone refractory prostate cancer: a changing natural history?
    Roberts-Thomson R; Rosenthal MA; Gonzales M; Drummond K
    Intern Med J; 2009 Mar; 39(3):205-6. PubMed ID: 19383072
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there still place for estrogens in the treatment of advanced prostatic carcinoma?
    Steg A
    Prog Clin Biol Res; 1987; 243B():429-34. PubMed ID: 3309995
    [No Abstract]   [Full Text] [Related]  

  • 16. Somatostatin analogues in the treatment of breast and prostate cancer.
    Manni A; Boucher AE; Demers LM; Harvey HA; Lipton A; Simmonds MA; Bartholomew M
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1083-7. PubMed ID: 1981012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogens: are they really dangerous? Groupe Coopératif d'étude sur le Cancer de la Prostate.
    Prog Clin Biol Res; 1987; 243B():437-8. PubMed ID: 3659036
    [No Abstract]   [Full Text] [Related]  

  • 19. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.